Treatment of cytokine mediated conditions

• 收藏
• 分享

专利权人:

Dilafor AB

发明人:

Eklund, Erik,Malmstrom, Anders,Ekman-Ordeberg, Gunvor

申请号：

AU2012203519

公开号：

AU2012203519A1

申请日:

2012.06.15

申请国别(地区):

AU

年份:

2014

代理人:

摘要：

#$%^&*AU2012203519A120140116.pdf#####Abstract The present invention relates to the usefulness of a sulfated glycosaminoglycan (GAG) selected from the group consisting of heparan sulfate (HS), depolymerised heparan sulfate, dermatan sulfate (DS), depolymerised dermatan sulfate, low molecular weight heparin (LMWH), and depolymerised heparin having an anti-factor Xa activity of 200 IU/mg or less in treatment or prevention of at least one cytokine mediated condition of the endothelial or epithelial linings.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/